Please login to the form below

Not currently logged in
Email:
Password:

IDO inhibitor

This page shows the latest IDO inhibitor news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in ... JAK1/JAK2 inhibitor Jakafi – given in combination with corticosteroids

Latest news

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    IDO1 inhibitor given alongside Opdivo, BMS’ CTLA4 inhibitor Yervoy (ipilimumab), other marketed cancer drugs and LAG-3 candidate relatlimab. ... Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also

  • NewLink pancreatic cancer vaccine flunks phase III test NewLink pancreatic cancer vaccine flunks phase III test

    efforts on its IDO checkpoint inhibitor programme. ... The IDO inhibitor pipeline is currently led by indoximod, which is in phase II for breast cancer (in combination with taxane drugs docetaxel and paclitaxel) and prostate cancer (in combination with

  • BMS buys immunotherapy specialist Flexus in $1.2bn deal BMS buys immunotherapy specialist Flexus in $1.2bn deal

    With the addition of a potentially best-in-class IDO1 inhibitor and the broad IDO/TDO programmes, Bristol-Myers Squibb will accelerate its ability to explore numerous immunotherapeutic approaches across tumour ... the development of our potentially

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Meanwhile, despite the mixed results for checkpoint inhibitor combinations to date, there’s no let-up in the pursuit of new cocktail recipes. ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor epacadostat bombed when paired with Keytruda in a

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    F001287, IDO1 inhibitor IDO/TDO discovery programme - immuno-oncology. Corporate acquisition. 1, 250. ... Abbreviations:. IDO, Indoleamine-2, 3-dioxygenase;  TDO, Tryptophan-2, 3- dioxygenase. COPD, chronic obstructive pulmonary disease.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics